Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

NCT01341496 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

41

Enrollment

NIH

Sponsor class

Conditions

Sarcoma
Melanoma
Epithelial Malignancies
Pleural Malignancy

Interventions

BIOLOGICAL: Epigenetically Modified Autologous Tumor
DRUG: Cyclophosphamide
DRUG: Celecoxib

Sponsor

National Cancer Institute (NCI)